Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15823888 | 0.98 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2USP2LMNACYP1A2 | |
| SCHEMBL2839889 | 0.91 | — | — | |
| SCHEMBL14165607 | 0.80 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2USP2LMNACYP1A2 | |
| SCHEMBL976812 | 0.80 | MME (0.44) | ALDH1A1P2RX7HTTMME | |
| SCHEMBL5220339 | 0.78 | HTT (0.38) | ALDH1A1SMN1; SMN2LMNAP2RX7HTT | |
| SCHEMBL3892858 | 0.78 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2USP2LMNACYP1A2 | |
| SCHEMBL2838140 | 0.78 | USP2 (0.33) | ALDH1A1SMN1; SMN2USP2LMNACYP1A2 | |
| SCHEMBL5221342 | 0.77 | CETP (0.36) | ALDH1A1LMNAP2RX7HTTMME | |
| SCHEMBL3373260 | 0.77 | CYP2C19 (0.42) | ALDH1A1SMN1; SMN2USP2LMNACYP1A2 | |
| SCHEMBL23715196 | 0.76 | MME (0.41) | ALDH1A1P2RX7HTTMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266951-A1 | Organic compounds | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20090253701-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-20090253703-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | US | disclosed |
| US-7582782-B2 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers | NOVARTIS AG (CH) | 2009-09-01 | — | — | US | disclosed |
| US-20070135498-A1 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers | NOVARTIS AG (CH) | 2007-06-14 | — | — | US | disclosed |
| EP-1689702-A1 | ORGANIC COMPOUNDS | NOVARTIS-PHARMA GMBH (AT) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051895-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253701-A1 | ORGANIC COMPOUNDS | AGTR1, AGTR2, REN | ALDH1A1 233/4885SMN1; SMN2 2362/4885USP2 4172/4885 |
| US-20090253703-A1 | ORGANIC COMPOUNDS | AGTR1, AGTR2, REN | ALDH1A1 233/4885SMN1; SMN2 2362/4885USP2 4172/4885 |
| US-20070135498-A1 | 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (1-hydroxymethyl-cyclopentyl)-amide; hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, alzheimers | AGTR1, REN, AGTR2 | ALDH1A1 453/4885SMN1; SMN2 2454/4885USP2 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.